A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

NCT02038777 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: PF-04449913
DRUG: PF-04449913
DRUG: Low dose ARA-C (LDAC)
DRUG: PF-04449913
DRUG: Daunorubicin
DRUG: Cytarabine
DRUG: PF-04449913
DRUG: Azacitidine
DRUG: PF-04449913
DRUG: LDAC

Sponsor

Pfizer